Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


12 new conditions added to NMS from September 1, including atrial fibrillation and osteoporosis

The new medicine service (NMS) will be expanded from September 1 to include more therapeutic areas, the Pharmaceutical Services Negotiating Committee (PSNC) has announced.

Twelve additional conditions have been added to the service, PSNC announced today (August 23), as it published the outcome of the negotiations on year three of the community pharmacy contractual framework.

The conditions previously covered by the service specification remain in place, the negotiator clarified, and an updated list of medicines that are suitable for and covered by the service will be published “shortly” by the NHS Business Services Authority.

The extra conditions that will be covered by the NMS are:

  • Acute coronary syndrome
  • Atrial fibrillation
  • Coronary heart disease
  • Epilepsy
  • Glaucoma
  • Gout
  • Heart failure
  • Hypercholesterolaemia
  • Osteoporosis
  • Parkinson’s Disease
  • Stroke/transient ischemic attack
  • Urinary incontinence and retention.


Increase in cap on number of NMSs


Following the expansion of the service, the cap on the number of paid NMSs that contractors can complete will also increase from 0.5% to 1% “of monthly prescription volume” and “additional bandings will also be included”, PSNC added.

Meanwhile, the maximum remuneration for the service remains at £28 per completed NMS.

As C+D previously reported, the eligibility criteria for the NMS are being widened to allow carers of patients and the parents or guardians of children to benefit from the service where the person they look after is not able to provide consent themselves.


Catch-up NMS temporarily available


Patients who were prescribed a new medicine during the pandemic, but who could not receive NMS support at the time, will be able to access a catch-up NMS.

“To further support patients as part of the NHS COVID-19 recovery plan, the temporary introduction of catch-up NMS has been agreed,” PSNC said.

“Further details on the requirements will shortly be published in an updated service specification,” it added.

What do you make of the outcome of PSNC's negotiations for year three of the five-year community pharmacy contractual framework?


Related Content


New Zealand
£ Competitive

Apply Now
Latest News & Analysis
See All



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts